Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc.

Jan 13, 2022

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Jan 07, 2022

Fortress Biotech to Participate in the H.C. Wainwright BioConnect Virtual Conference

Jan 06, 2022

Mustang Bio to Participate in Three January 2022 Virtual Investor Conferences

Jan 05, 2022

Fortress Biotech to Ring Nasdaq Stock Market Closing Bell on December 21

Dec 21, 2021

Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV

Dec 16, 2021

Mustang Bio Added to the NASDAQ Biotechnology Index

Dec 16, 2021

Avenue Therapeutics Announces Closing of Public Offering of Common Stock

Dec 15, 2021

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Dec 13, 2021

Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock

Dec 12, 2021